Esomeprazole-Naproxen

• Osteoarthritis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• NSAID-Associated Ulcer Prevention

Esomeprazole/naproxen is a fixed-dose combination medication containing a proton pump inhibitor and a nonsteroidal anti-inflammatory drug (NSAID), designed to provide pain relief while reducing the risk of gastric ulcers associated with long-term NSAID use.

Mechanism of Action

This combination works through two complementary mechanisms. Naproxen is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This provides analgesic, anti-inflammatory, and antipyretic effects but also reduces gastroprotective prostaglandins, increasing gastric ulcer risk. Esomeprazole is the S-isomer of omeprazole, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. By combining these agents, the formulation provides NSAID-related pain relief while mitigating gastrointestinal risk through acid suppression.

Available Formulations

Esomeprazole/naproxen is available as delayed-release tablets containing esomeprazole 20 mg with naproxen 375 mg or 500 mg. The tablets have a unique multilayer design with an immediate-release esomeprazole component in the outer layer and an enteric-coated naproxen core. The tablets should be swallowed whole with liquid and should not be crushed, chewed, or split.

Medical Uses

Esomeprazole/naproxen is FDA-approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It is intended for patients who would otherwise require an NSAID plus a PPI. The combination is not intended for initial treatment of acute pain situations where a faster onset is needed.

Dosing Guidelines

The recommended dose is one tablet (either 375 mg or 500 mg naproxen component) twice daily, at least 30 minutes before meals. The naproxen 500 mg/esomeprazole 20 mg tablet should be used for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Patients should use the lowest effective dose for the shortest duration. Swallow tablets whole; do not split, chew, or crush. The delayed-release formulation means onset may be slower than with immediate-release naproxen.

Important Safety Information

This medication carries boxed warnings for cardiovascular risk (increased risk of serious cardiovascular thrombotic events, including MI and stroke, especially with long-term use or in patients with cardiovascular disease) and gastrointestinal risk (increased risk of serious GI adverse events including bleeding, ulceration, and perforation, which can be fatal). NSAIDs are contraindicated in the setting of coronary artery bypass graft surgery. Other serious risks include hypertension, heart failure, renal effects, hepatotoxicity, serious skin reactions, and hematologic effects.

Drug Interactions

Naproxen may reduce the antihypertensive effect of ACE inhibitors, ARBs, and beta-blockers. Concurrent use with diuretics may impair renal function. Lithium levels may increase. Anticoagulant effect of warfarin may be enhanced. Esomeprazole may reduce absorption of drugs requiring gastric acidity (ketoconazole, iron, erlotinib). Clopidogrel effectiveness may be reduced; avoid combination. Methotrexate levels may increase; monitor toxicity.

Special Populations

This medication is contraindicated in the third trimester of pregnancy due to risk of premature closure of the fetal ductus arteriosus; avoid use during all trimesters if possible. NSAIDs are present in breast milk; use caution. Safety and efficacy have not been established in pediatric patients. Elderly patients are at greater risk for serious GI events and should use with caution. The medication is not recommended in patients with moderate to severe renal impairment (CrCl less than 30 mL/min). Avoid use in patients with severe hepatic impairment.